3-amino-N-(4-iodo-phenyl)-benzamide | 115175-18-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-amino-N-(4-iodo-phenyl)-benzamide
• 英文别名: 3-amino-N-(4-iodophenyl)benzamide
• CAS: 115175-18-3
• 化学式: C₁₃H₁₁IN₂O
• mdl: MFCD11176476
• 分子量: 338.148
• InChiKey: UAAOPAMHOFEPJI-UHFFFAOYSA-N

物化性质

• 沸点：
  383.2±27.0 °C(predicted)
• 密度：
  1.755±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-ethyl-5-(2-methyl-[1,3]dioxolan-2-yl)-2-oxo-2,3-dihydro-1H-indole-3-carboxylic acid methyl ester 、 3-amino-N-(4-iodo-phenyl)-benzamide 生成 5-Acetyl-1-ethyl-2-oxo-2,3-dihydro-1H-indole-3-carboxylic acid [3-(4-iodo-phenylcarbamoyl)-phenyl]-amide
  参考文献：
  名称：

  METHOD OF INHIBITION OF HUMAN GLYCOGEN PHOSPHORYLASE

  摘要：

  本发明涉及一种新型的糖原磷酸化酶抑制剂的结合位点，该结合位点位于糖原磷酸化酶酶内。该新型结合位点允许设计新型的糖原磷酸化酶抑制剂。

  公开号：

  US20020031816A1

文献信息

• Inhibitors of human glycogen phosphorylase
  申请人：Pfizer Products Inc.

  公开号：EP0978279A1

  公开（公告）日：2000-02-09

  The present invention is directed to a novel binding site for a glycogen phosphorylase inhibitor found within a glycogen phosphorylase enzyme. The novel binding site allows the design novel of glycogen phosphorylase inhibitors.

  本发明涉及一种在糖原磷酸化酶酶内发现的新型糖原磷酸化酶抑制剂结合位点。该新型结合位点使得能够设计新型的糖原磷酸化酶抑制剂。
• Use of glycogen phosphorylase inhibitors
  申请人：——

  公开号：US20030004162A1

  公开（公告）日：2003-01-02

  The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

  本发明提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用有效量的糖原磷酸化酶抑制剂；有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。本发明还提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用包含有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂的药物组合物；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。
• Glycogen phosphorylase inhibitors
  申请人：Pfizer Inc

  公开号：US05998463A1

  公开（公告）日：1999-12-07

  This invention relates to certain 5-acyl-2-oxo-indole-3-carboxamides useful as inhibitors of glycogen phosphorylase, methods of treating glycogen phosphorylase dependent diseases or conditions with such compounds and pharmaceutical compositions comprising such compounds. This invention also relates to pharmaceutical compositions comprising those 5-acyl-2-oxo-indole-3-carboxamides in combination with antidiabetes agents and methods of treating glycogen phosphorylase dependent diseases or conditions with such compositions.

  这项发明涉及某些5-酰基-2-氧代吲哚-3-甲酰胺，它们作为糖原磷酸化酶的抑制剂是有用的，涉及使用这些化合物治疗糖原磷酸化酶依赖性疾病或病症的方法，以及包含这些化合物的药物组合物。该发明还涉及包含那些5-酰基-2-氧代吲哚-3-甲酰胺与抗糖尿病剂组合的药物组合物，以及使用这些组合物治疗糖原磷酸化酶依赖性疾病或病症的方法。
• US5998463A
  申请人：——

  公开号：US5998463A

  公开（公告）日：1999-12-07